Risk of recurrence and bleeding with Rivaroxaban among patients with venous thromboembolism and active cancer

Introduction: Anticoagulant treatment in cancer patients with venous thromboembolism (VTE) is challenging due to cancer-associated hypercoagulability and increased bleeding risk. Low-molecular-weight-heparin (LMWH) is the recommended treatment but rivaroxaban could be an attractive alternative because the once daily, oral dosing obviates the need for subcutaneous injections combined with short half-life and lower price.
Source: Thrombosis Research - Category: Hematology Authors: Tags: PO-84 Source Type: research